Loading…
← CockpitCompetitor Analysis › 7476.T AS ONE CorporationOpen in the cockpit ↗

AS ONE Corporation7476.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Distributors

Japanese distributor of laboratory and medical equipment and consumables to research institutions and hospitals.

≈ Japan's Fisher Scientific (lab supply distribution)Momentum leader 83
Mkt cap
$1.10B
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$2.75M
20-day average traded
Fwd P/E
18.4×
forward earnings
ROIC−WACC
+10.1 pp
WACC 6.6%
Hurdle
-6 pp
Req g minus delivered
Next earnings
72 days
29 Jan 2027
Close · JPY¥2,517
1D-1.2%
1W+1.3%
1M-2.6%
3M+5.7%
6M+24.5%
YTD+4.7%
1Y+2.8%
ATR %2.5%
52w lowhigh6.0% off high

What AS ONE does

Japanese distributor of laboratory and medical equipment and consumables to research institutions and hospitals.

Sells from a large catalogue, in print and online, of lab and clinical supplies from many makers, so a lab can order thousands of small items from one source; its own-brand products carry better margins than resold goods. Japan is the core, with operations in China and elsewhere in Asia.

In one line: Japan's Fisher Scientific (lab supply distribution).

Products and services

  • Laboratory equipment/consumables
  • Medical equipment distribution
  • E-commerce catalog sales

Customers

  • Universities/research labs
  • Hospitals
  • Pharmaceutical/biotech companies

Where it sits in the supply chain

  • Health care
  • Laboratory/medical distribution
  • Lab equipment, consumables, medical…

What could go right

  • Research/biotech spending growth

What could go wrong

  • Distribution margin pressure

Moat: narrow (distribution, scale). Broad catalog and logistics network for lab supplies built over decades.

Headquarters: Tokyo, Japan · Founded: 1948 · Employees: 758

Named competitors

AS ONE at a glance

Size AS ONE (7476.T) is a Japan Health Care company (Medical Distributors) with a market value of $1.10B, the 700th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,517 on 18 Nov 2026.

Performance Over six months the shares gained 24.5%, against -3.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 9.8% over the last twelve months (peer median +5.0%); the operating margin is 11.7% (peer median 2.3%).

Valuation It trades at 18.4× forward earnings against a peer median of 15.3× (5th most expensive of 12).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -6 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 10.1 points above its cost of capital (6.6% WACC).

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 20267476.T 124Peer median 96
Six months, rebased to 100: AS ONE against the median of its 20 peers (local-currency closes).

AS ONE financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥117B¥111B¥104B¥95.5B¥91.4B
Revenue growth—+7%+9%+5%—
Gross profit¥35.3B¥33.5B¥31.3B¥29.2B¥28.5B
EBITDA¥15.5B¥14.7B¥13.4B¥12.3B¥13.0B
Net income¥9.58B¥9.18B¥8.23B¥7.50B¥8.11B
Free cash flown/a¥4.42B¥8.11B¥5.55B¥6.40B
Capital expendituren/a¥2.75B¥1.79B¥1.58B¥1.15B
Total debt¥8.36B¥4.75B¥7.21B¥3.65B¥6.27B

Quarterly statements and history in the cockpit →

AS ONE competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%0%+20%600587DOCM301584600713603368ARJO-BENTERO68263360RDCNEU6006283013709987008930605136ASKER7476.T6-month return →1-month return →
Up and to the right = strong over both horizons. AS ONE is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%20×40×600587603368ARJO-BENTERO68263360NEU8129ASKER7476.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. AS ONE is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%600587301584603368ARJO-BENTERO68263360NEU8129301370008930605136ASKER7476.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. AS ONE is the large dot.

AS ONE competitors and peer comparison

Head to head with its named competitors (7476.T vs 3360.T vs TMO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
AS ONE 7476.T$1.10B+25%+10%12%18.4×0.0%
Ship Healthcare 3360.T$1.38B+19%+6%3%14.6×-14.5%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%

How AS ONE compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AS ONE against its 20 peers (data as of 18 Nov 2026)
Measure7476.TPeer medianRank in peer set
1-month return-2.6%-0.1%8th lowest of 21
6-month return+24.5%-3.7%6th highest of 21
Distance from 52-week high-6.0%-20.2%2nd highest of 21
Revenue growth (TTM)+9.8%+5.0%5th highest of 21
Operating margin11.7%2.3%highest of 21
Forward P/E18.4×15.3×5th most expensive of 12
Growth the price implies (Req g, 7 yrs)0.0%-1.3%8th most demanding of 17
Growth delivered (Del g)+6.3%+6.7%9th highest of 17
Hurdle (Req g minus delivered)-6.3 pp-6.7 pp9th least demanding of 17
ROIC minus cost of capital+10.1 pp+0.3 pp2nd highest of 21
EV / EBITDA10.1×n/a—
Net debt / EBITDA-1.2×1.6×4th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%47.7×24.7%+29.9%
Shanghai Haohai Biological Technology 6826.HKHong Kong$897M-24%-5%-2%7.7×17.0%+12.4%
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Neuca NEU.WAPoland$795M-9%+8%2%15.3×5.3%+8.1%
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Arata 2733.TJapan$576M-3%+3%1%12.0×-6.2%+3.8%
Shanghai New World 600628.SSChina$573M-10%-2%6%n/a-1.6%+1.0%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%n/a13.1%+7.5%
Suzuken 9987.TJapan$2.36B+8%+5%1%15.8×-10.4%+3.2%
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%n/a26.0%+9.6%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%n/a21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%n/an/an/a
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%24.8×4.7%+12.7%

Questions

Who are AS ONE's main competitors?
Named competitors: Ship Healthcare Holdings (3360.T), Thermo Fisher Scientific (TMO). The cockpit's measured peer set (industry) also includes Shinva Medical Instrument (600587.SS), DocMorris (DOCM.SW), Shanghai C and D INNOSTIC Medical Technology (301584.SZ), Nanjing Pharmaceutical (600713.SS), Guangxi LiuYao (603368.SS), Arjo (ARJO-B.ST).
Is AS ONE expensive compared with its peers?
On forward p/e it trades at 18.4× against a peer median of 15.3×, 5th most expensive of 12 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -6 pp: the price already allows for a slowdown.
How has AS ONE stock performed?
Over six months to 18 Nov 2026 the shares returned +24.5% against -3.7% for the median peer; over one year +2.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.